Pharmacological stabilization of intracranial aneurysms in mice: A feasibility study

Stroke

Volumn 43, Issue 9, 2012, Pages 2450-2456

  Makino, Hiroshi ^a,b   Tada, Yoshiteru ^a,b,c   Wada, Kosuke ^a,b   Liang, Elena I ^a,b   Chang, Mayland ^d   Mobashery, Shahriar ^d   Kanematsu, Yasuhisa ^c   Kurihara, Chie ^a,b   Palova, Emma ^a,b   Kanematsu, Miyuki ^c   Kitazato, Keiko ^c   Hashimoto, Tomoki ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

^d UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

animal model; inflammation; intracranial aneurysm; intracranial hemorrhage; matrix metalloproteinase; subarachnoid hemorrhage; tetracycline

Indexed keywords

DOXYCYCLINE; ELASTASE; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE INHIBITOR; MINOCYCLINE; SB 3CT; TETRACYCLINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN ARTERY ANEURYSM RUPTURE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG STABILITY; ENZYME ACTIVITY; FEASIBILITY STUDY; HYPERTENSION; INTRACRANIAL ANEURYSM; MALE; MOUSE; NEUROLOGIC EXAMINATION; NONHUMAN; PRIORITY JOURNAL; SUBARACHNOID HEMORRHAGE; TREATMENT RESPONSE;

ANEURYSM, RUPTURED; ANIMALS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; DOXYCYCLINE; FEASIBILITY STUDIES; GELATINASES; HETEROCYCLIC COMPOUNDS, 1-RING; INTRACRANIAL ANEURYSM; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED C57BL; MINOCYCLINE; NEUROLOGIC EXAMINATION; PROTEASE INHIBITORS; SUBARACHNOID HEMORRHAGE; SULFONES; SURVIVAL ANALYSIS; TETRACYCLINES;

EID: 84865604836     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.112.659821     Document Type: Article

References (26)

1. Wiebers DO, Whisnant JP, Huston J III, Meissner I, Brown RD Jr, Piepgras DG, et al. Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet. 2003;362:103-110.
2. Berman MF, Solomon RA, Mayer SA, Johnston SC, Yung PP. Impact of hospital-related factors on outcome after treatment of cerebral aneurysms. Stroke. 2003;34:2200-2207.
3. Chyatte D, Bruno G, Desai S, Todor DR. Inflammation and intracranial aneurysms. Neurosurgery. 1999;45:1137-1146.
4. Shi C, Awad IA, Jafari N, Lin S, Du P, Hage ZA, et al. Genomics of human intracranial aneurysm wall. Stroke. 2009;40:1252-1261.
5. Kim SC, Singh M, Huang J, Prestigiacomo CJ, Winfree CJ, Solomon RA, et al. Matrix metalloproteinase-9 in cerebral aneurysms. Neurosurgery. 1997;41:642-666.
6. Frosen J, Piippo A, Paetau A, Kangasniemi M, Niemela M, Hernesniemi J, et al. Remodeling of saccular cerebral artery aneurysm wall is associated with rupture: histological analysis of 24 unruptured and 42 ruptured cases. Stroke. 2004;35:2287-2293.
7. Kanematsu Y, Kanematsu M, Kurihara C, Tada Y, Tsou TL, van Rooijen N, et al. Critical roles of macrophages in the formation of intracranial aneurysm. Stroke. 2011;42:173-178.
8. Hasan DM, Mahaney KB, Brown RD Jr, Meissner I, Piepgras DG, Huston J, et al. Aspirin as a promising agent for decreasing incidence of cerebral aneurysm rupture. Stroke. 2011;42:3156-3162.
9. Peterson JT. Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail Rev. 2004;9:63-79.
10. Romero-Perez D, Fricovsky E, Yamasaki KG, Griffin M, Barraza-Hidalgo M, Dillmann W, et al. Cardiac uptake of minocycline and mechanisms for in vivo cardioprotection. J Am Coll Cardiol. 2008;52: 1086-1094.
11. Baxter BT, Pearce WH, Waltke EA, Littooy FN, Hallett JW Jr, Kent KC, et al. Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (Phase II) multicenter study. J Vasc Surg. 2002;36:1-12.
12. Frenzel T, Lee CZ, Kim H, Quinnine NJ, Hashimoto T, Lawton MT, et al. Feasibility of minocycline and doxycycline use as potential vasculo-static therapy for brain vascular malformations: pilot study of adverse events and tolerance. Cerebrovasc Dis. 2008;25:157-163.
13. Nuki Y, Tsou TL, Kurihara C, Kanematsu M, Kanematsu Y, Hashimoto T. Elastase-induced intracranial aneurysms in hypertensive mice. Hypertension. 2009;54:1337-1344.
14. -/- mice results in accelerated atherosclerosis: the role of angiotensin ii. Hypertension. 2008;51:218-224.
15. Kanematsu Y, Kanematsu M, Kurihara C, Tsou TL, Nuki Y, Liang EI, et al. Pharmacologically induced thoracic and abdominal aortic aneurysms in mice. Hypertension. 2010;55:1267-1274.
16. Jeon H, Ai J, Sabri M, Tariq A, Shang X, Chen G, et al. Neurological and neurobehavioral assessment of experimental subarachnoid hemorrhage. BMC Neurosci. 2009;10:103.
17. Chan PH. Oxygen radicals in focal cerebral ischemia. Brain Pathol. 1994;4:59-65.
18. Yang G, Chan PH, Chen J, Carlson E, Chen SF, Weinstein P, et al. Human copper-zinc superoxide dismutase transgenic mice are highly resistant to reperfusion injury after focal cerebral ischemia. Stroke. 1994; 25:165-170.
19. Huang Z, Huang PL, Panahian N, Dalkara T, Fishman MC, Moskowitz MA. Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. Science. 1994;265:1883-1885.
20. Pyo R, Lee JK, Shipley JM, Curci JA, Mao D, Ziporin SJ, et al. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest. 2000;105:1641-1649.
21. Ota R, Kurihara C, Tsou TL, Young WL, Yeghiazarians Y, Chang M, et al. Roles of matrix metalloproteinases in flow-induced outward vascular remodeling. J Cereb Blood Flow Metab. 2009;29:1547-1558.
22. Brown S, Bernardo MM, Li ZH, Kotra LP, Tanaka Y, Fridman R, et al. Potent and selective mechanism-based inhibition of gelatinases. J Am Chem Soc. 2000;122:6799-6800.
23. Elewa HF, Hilali H, Hess DC, Machado LS, Fagan SC. Minocycline for short-term neuroprotection. Pharmacotherapy. 2006;26:515-521.
24. Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a Phase III randomised trial. Lancet Neurol. 2007;6: 1045-1053.
25. Zhao BQ, Tejima E, Lo EH. Neurovascular proteases in brain injury, hemorrhage and remodeling after stroke. Stroke. 2007;38:748-752.
26. Rosenberg GA, Estrada EY, Mobashery S. Effect of synthetic matrix metalloproteinase inhibitors on lipopolysaccharide-induced blood-brain barrier opening in rodents: differences in response based on strains and solvents. Brain Res. 2007;1133:186-192.